Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Standard 2016-2017 Flu vaccine refers to the standard-dose seasonal influenza vaccine used as a comparator in clinical research conducted by the University Health Network (UHN) in Toronto. During the 2016-2017 influenza season, this vaccine was typically a trivalent or quadrivalent inactivated influenza vaccine (IIV) containing 15 μg of hemagglutinin per viral strain. It was evaluated in adult solid organ transplant (SOT) recipients to determine if a high-dose formulation (containing 60 μg per strain) provided superior immunogenicity. The vaccine works by inducing neutralizing antibodies against the hemagglutinin protein of specific influenza A and B strains selected by the World Health Organization for that season.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Standard 2016-2017 Flu vaccine.